News | April 05, 2007

Spectranetics’ New Ablation System for PAD Now Available

April 6, 2007 — Spectranetics Corp., Colorado Springs, CO, has announced the commercial availability of the TURBO elite product line for excimer laser ablation to treat peripheral artery disease (PAD). The TURBO elite product line features an enhanced outer jacket and inner guide wire lumen with optimized ablation efficiency and energy output that enables increased penetration rates.

The system vaporizes lipid-based, calcified and fibrotic plaque as well as neointimal hyperplasia. And the company says that the TURBO elite incorporates all of the features of the TURBO product line, including 80 hertz laser repetition rates, “continuous on” lasing and a hydrophilic coating. TURBO elite catheters are available in a variety of sizes.

“Laser ablation is an extremely safe and effective minimally invasive peripheral intervention treatment option,” said Dr. Craig Walker of The Cardiovascular Institute of the South, and a member of the editorial board of Diagnostic & Invasive Cardiology. “It is successful in removing plaque and clot from blocked arteries to establish blood flow to the limbs. It requires less time and seems to have a lower risk than many other procedures that restore blood flow. Multiple publications have reported greater than 90 percent limb salvage rates without the need for open surgery in patients presenting with critical limb ischemia.

“The excimer laser ablation procedure usually takes only minutes. Patients remain awake during the entire procedure and typically experience no discomfort,” Dr. Walker continued. Spectranetics’ TURBO elite product line received FDA market clearance in October 2006 and launched a limited market release in the fourth quarter of 2006.

The full product line is currently commercially available. For more information visit www.spectranetics.com

Related Content

Intact Vascular Inc. received U.S. Food and Drug Administration (FDA) market clearance for the Tack Endovascular System. This is a purpose-built dissection repair device implanted post-angioplasty in patients with peripheral arterial disease (PAD).
Technology | Peripheral Artery Disease (PAD) | April 15, 2019
April 15, 2019 – Intact Vascular Inc. received U.S.
The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

Feature | Peripheral Artery Disease (PAD) | January 30, 2019 | Dave Fornell, Editor
In recent years, there has been a lot of focus by vendors on developing better stenting technologies to treat...
The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

Feature | Peripheral Artery Disease (PAD) | January 25, 2019 | Dave Fornell, Editor
The anti-proliferative drug paclitaxel has been used as a coating on coronary stents to prevent restenosis since 2003
Lumee Oxygen Platform Measures Treatment Response in Critical Limb Ischemia
News | Peripheral Artery Disease (PAD) | January 25, 2019
January 25, 2019 — Profusa announced promising...
BEST-CLI Trial Examining Critical Limb Ischemia Treatment Options Nears Enrollment Goal
News | Peripheral Artery Disease (PAD) | January 23, 2019
A new report in the Journal of Vascular Surgery chronicles a multi-site randomized controlled trial comparing treatment...
FDA Issues Letter About Paclitaxel Coated Balloons and Eluting Stents
News | Peripheral Artery Disease (PAD) | January 17, 2019
The U.S. Food and Drug Administration (FDA) issued a letter Jan. 17, 2019, to healthcare providers regarding a recent...
New Appropriate Use Criteria Released for Peripheral Artery Interventions
News | Peripheral Artery Disease (PAD) | December 19, 2018
A new set of appropriate use criteria (AUC) released Dec. 17 by a group of cardiovascular professional societies...
Lithotripsy Safe and Effective in Calcified Stenotic Peripheral Arteries
News | Peripheral Artery Disease (PAD) | December 04, 2018
New results from the DISRUPT PAD II study showed no perforations, embolization, reflow or abrupt closures with the...
Lutonix 014 Drug-Coated Balloon Safe and Effective Below the Knee
News | Peripheral Artery Disease (PAD) | November 07, 2018
The Lutonix Drug-Coated Balloon (DCB) showed statistically significant safety equivalence with a standard percutaneous...
Overlay Init